Well Controlled Blood Pressure in Turkish Patients: How Many Drugs Are Required to Attain and Maintain the Blood Pressure Goal? — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Well Controlled Blood Pressure in Turkish Patients: How Many Drugs Are Required to Attain and Maintain the Blood Pressure Goal?
Medicana International Hospital, Department of Internal Medicine, School of Medicine, Biruni University, Istanbul, Turkey
,
Medicana International Hospital, Department of Internal Medicine, School of Medicine, Biruni University, Istanbul, Turkey
,
Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey
,
Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey
,
Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey
1 Medicana International Hospital, Department of Internal Medicine, School of Medicine, Biruni University, Istanbul, Turkey
2 Medicana International Hospital, Department of Internal Medicine, School of Medicine, Biruni University, Istanbul, Turkey
3 Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey
4 Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey
5 Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey
Background: This study aimed to determine the number of antihypertensive agents required to achieve optimal blood pressure (BP) in Turkish hypertensive patients. Material and Methods: Totally 400 hypertensive patients (114 males and 286 females) were enrolled. BP was measured by patients at home twice a day. The patients were called for controlling in every four weeks, and those who had BP < 140/90 were not followed-up. In patients with BP > 140/90 drug, doses were increased or another antihypertensive drug added and the patients were continued to be followed-up. Results: In the first follow-up (on the 4 th week), 152 (38%) patients, including 35 (31%) men and 117 (41%) women, attained the goal BP. The mean duration of hypertension in single, double, triple, and quadruple treatment groups was 6.2 ± 5.0, 6.8 ± 5.9, 8.8 ± 5.4, and 10.4 ± 6.6 years, respectively. In the beginning, the median number of agents used for each patient was 2.17. When the follow-up was concluded, the median of agents used for each patient was 2.72. Conclusion: Thirty-eight percent of participants had controlled hypertension in the first follow-up. Women had better BP control. The median number of agents required for attaining and maintaining BP goal was 2.72. More drugs are needed when hypertension gets longer.
Kearney, P.M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P.K. and He, J. (2005) Global Burden of Hypertension: Analysis of Worldwide Data. Lancet, 365, 217-223. https://doi.org/10.1016/S0140-6736(05)17741-1
Marma, A.K. and Lloyd-Jones, D.M. (2009) Systematic Examination of the Updated Framingham Heart Study General Cardiovascular Risk Profile. Circulation, 120, 384-390. https://doi.org/10.1161/CIRCULATIONAHA.108.835470
Chobanian, A.V. (2009) The Hypertension Paradox—More Uncontrolled Disease Despite Improved Therapy. New England Journal of Medicine, 361, 878-887. https://doi.org/10.1056/NEJMsa0903829
Lloyd-Jones, D.M., Evans, J.C. and Levy, D. (2005) Hypertension in Adults across the Age Spectrum: Current Outcomes and Control in the Community. JAMA, 294, 466-472.
Lewington, S., Clarke, R., Qizilbash, N., Peto, R. and Collins, R. (2002) Age-Specific Relevance of Usual Blood Pressure to Vascular Mortality: A Meta-Analysis of Individual Data for One Million Adults in 61 Prospective Studies. Lancet, 360, 1903-1913. https://doi.org/10.1016/S0140-6736(02)11911-8
Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., et al. (2013) ESH/ESC Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 34, 2159-2219. https://doi.org/10.1093/eurheartj/eht151
James, P.A., Oparil, S., Carter, B.L., et al. (2014) Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA, 311, 507-520.
American Diabetes Association (2013) Standards of Medical Care in Diabetes—2013. Diabetes Care, 36, S11-S66. https://doi.org/10.2337/dc13-S011
KDIGO (2012) Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International Supplements, 2, 341-342.
Mancia, G. and Grassi, G. (2020) Systolic and Diastolic Blood Pressure Control in Antihypertensive Trials. Journal of Hypertension, 20, 1461-1464. https://doi.org/10.1097/00004872-200208000-00001
Wolf-Maier, K., Cooper, R.S., Kramer, H., Banegas, J.R., Giampaoli, S., Joffres, M.R., et al. (2004) Hypertension Treatment and Control in Five European Countries, Canada, and the United States. Hypertension, 43, 10-17. https://doi.org/10.1161/01.HYP.0000103630.72812.10
Ong, K.I., Cheung, B.M., Man, Y.B., Lau, C.P. and Lam, K.S.L. (2007) Prevalence, Awareness, Treatment, and Control of Hipertension among United States Adults 1999-2004. Hypertension, 49, 69-75. https://doi.org/10.1161/01.HYP.0000252676.46043.18
Erdine, S. and Aran, S.N. (2004) Current Status of Hypertension Control around the World. Clinical and Experimental Hypertension, 26, 731-738. https://doi.org/10.1081/CEH-200032144
Kearney, P., Whelton, M., Reynolds, K., Whelton, P.K. and He, J. (2004) Worldwide Prevalence of Hypertension: A Systematic Review. Journal of Hypertension, 22, 11-19. https://doi.org/10.1097/00004872-200401000-00003
Hajjar, I. and Kotchen, T.A. (2003) Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000. JAMA, 290, 199-206.
Peralta, C.A., Hicks, L.S., Chertow, G.M., Ayanian, J.Z., Vittinghoff, E., Lin, F., et al. (2005) Control of Hypertension in Adults with Chronic Kidney Disease in the United States. Hypertension, 45, 1119-1124. https://doi.org/10.1161/01.HYP.0000164577.81087.70
Burt, V.L., Whelton, P., Roccella, E.J., Brown, C., Cutler, J.A., Higgins, M., et al. (1995) Prevalence of Hypertension in the US Adult Population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension, 25, 305-313. https://doi.org/10.1161/01.HYP.25.3.305
Ong, K.L., Tso, A.W., Lam, K.S. and Cheung, B.M. (2008) Gender Difference in Blood Pressure Control and Cardiovascular Risk Factors in Americans with Diagnosed Hypertension. Hypertension, 51, 1142-1148. https://doi.org/10.1161/HYPERTENSIONAHA.107.105205
Macedo, M.E., Lima, M.J., Silva, A.O., Alcantara, P., Ramalhinho, V. and Carmona, J. (2005) Prevalence, Awareness, Treatment and Control of Hypertension in Portugal: The PAP Study. Journal of Hypertension, 23, 1661-1666. https://doi.org/10.1097/01.hjh.0000179908.51187.de
Meisinger, C., Heier, M., Völzke, H., Löwel, H., Mitusch, R., Hense, H.-W., et al. (2006) Regional Disparities of Hypertension Prevalence and Management within Germany. Journal of Hypertension, 24, 293-299. https://doi.org/10.1097/01.hjh.0000200508.10324.8e
Wyatt, S.B., Akylbekova, E.L., Wofford, M.R., Coady, S.A., Walker, E.R., Andrew, M.E., et al. (2008) Prevalence, Awareness, Treatment, and Control of Hypertension in the Jackson Heart Study. Hypertension, 51, 650-656. https://doi.org/10.1161/HYPERTENSIONAHA.107.100081
Pereira, M., Lunet, N., Azevedo, A. and Barros, H. (2009) Differences in Prevalence, Awareness, Treatment and Control of Hypertension between Developing and Developed Countries. Journal of Hypertension, 27, 963-975. https://doi.org/10.1097/HJH.0b013e3283282f65
UK Prospective Diabetes Study Group (1998) Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38. BMJ, 317, 703-713. https://doi.org/10.1136/bmj.317.7160.703
Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.-H., et al. (2001) Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with type 2 Diabetes and Nephropathy. New England Journal of Medicine, 345, 861-869. https://doi.org/10.1056/NEJMoa011161
Dahlöf, B., Sever, P.S., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M., et al. (2005) Prevention of Cardiovascular Events with an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required Versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Trial. Lancet, 366, 895-906. https://doi.org/10.1016/S0140-6736(05)67185-1
Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlöf, B., Elmfeldt, D., Julius, S., et al. (1998) Effects of intensive Blood-Pressure Lowering and Low-Dose Aspirin in Patients with Hypertension: Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial. HOT Study Group. Lancet, 351, 1755-1762. https://doi.org/10.1016/S0140-6736(98)04311-6
Peterson, J.C., Adler, S., Burkart, J.M., Greene, T., Hebert, L.A., Hunsicker, L.G., et al. (1995) Blood Pressure Control, Proteinuria, and the Progression of Renal Disease: The Modification of Diet in Renal Disease Study. Annals of Internal Medicine, 123, 754-762. https://doi.org/10.7326/0003-4819-123-10-199511150-00003
Calhoun, D.A., Lacourciere, Y., Chiang, Y.T. and Glazer, R.D. (2009) Triple Antihypertensive Therapy with Amlodipine, Valsartan, and Hydrochlorothiazide: A Randomized Clinical Trial. Hypertension, 54, 32-39. https://doi.org/10.1161/HYPERTENSIONAHA.109.131300
National Collaborating Centre for Chronic Conditions (2006) Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update. London: Royal College of Physicians.
Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M.J., et al. (2009) Reappraisal of European Guidelines on Hypertension Management: A European Society of Hypertension Task Force Document. Journal of Hypertension, 27, 2121-2158. https://doi.org/10.1097/HJH.0b013e328333146d
Julius, S., Kjeldsen, S.E., Brunner, H., et al. (2003) VALUE Trial: Long-Term Blood Pressure Trends in 13,449 Patients with Hypertension and High Cardiovascular Risk. American Journal of Hypertension, 16, 544-548. https://doi.org/10.1016/S0895-7061(03)00904-X
Nesbitt, S.D. (2007) Antihypertensive Combination Therapy: Optimizing Blood Pressure Control and Cardiovascular Risk Reduction. The Journal of Clinical Hypertension, 9, 26-32. https://doi.org/10.1111/j.1524-6175.2007.07724.x
Sica, D.A. (2002) Rationale for Fixed-Dose Combinations in the Treatment of Hypertension: The Cycle Repeats. Drugs, 62, 443-462. https://doi.org/10.2165/00003495-200262030-00003
Chapman, N., Dobson, J., Wilson, S., et al. (2007) Effect of Spironolactone on Blood Pressure in Subjects with Resistant Hypertension. Hypertension, 49, 839-845. https://doi.org/10.1161/01.HYP.0000259805.18468.8c
Primenta, E. and Calhoun, DA. (2010) Treatment of Resistant Hypertension. Journal of Hypertension, 28, 2194-2195. https://doi.org/10.1097/HJH.0b013e32833eafa3